- Gene
therapy could help overcome barriers that currently stand in the way of a
cure for cancer
- Genprex
is developing innovative, gene-based approaches toward the treatment of
cancer, specifically non-small cell lung cancer
- Clinical
trials so far have yielded encouraging data regarding the efficacy and
safety of the company’s product candidate, Oncoprex
Gene therapy could potentially advance the creation and
delivery of effective cancer treatments in the years to come. Various companies
are leading the way, and pioneers such as Genprex Inc. (NASDAQ: GNPX) are pushing for the
introduction of innovative and targeted therapies that have the potential to help
patients with various malignancies.
Gene therapy refers to the therapeutic delivery of DNA or
RNA to the cells of a patient for the purpose of treating a disease. It was
first conceptualized in 1972, and some of the first successful gene therapy
trials took place in the 1990s (http://ibn.fm/ioJWo).
Today, Genprex is working on an innovative, gene
therapy-based approach for the treatment of non-small cell lung cancer (NSCLC).
The company’s initial product candidate is called Oncoprex immunogene therapy,
and it encapsulates a tumor suppressor gene (TUSC2) that is delivered through
cholesterol nanoparticles.
Oncoprex is administered intravenously. According to Genprex
CEO Rodney Varner, Oncoprex allows a systemic and targeted approach toward the
treatment of NSCLC, because the nanoparticles are attracted to the cancer cells
like a magnet.
Once Oncoprex reaches the cancer cells, TUSC2 is expressed
into a protein that restores some of the defective gene functions arising in
cancer cells, and the nanoparticles are taken up at a rate that’s up to
25-times higher than in the case of normal cells.
Research suggests that Oncoprex is synergistic with targeted
and immunotherapies, and research has also shown that Oncoprex delivers results
in several ways. It interrupts the proliferation of cancer cells, helps cancer
cell death and modulates the immune response against cancer cells. In addition,
Oncoprex blocks mechanisms that can contribute to drug resistance and has demonstrated
minimal side effects compared to other lung cancer drugs.
Currently, Genprex holds more than 30 patents for its
platform technologies. The company has also recruited renowned scientists,
forming a powerful team that features some of the brightest minds in biotech,
oncology and clinical research.
Genprex is now conducting the second phase of a phase I/II
clinical trial. It also plans to expand its pipeline through the addition of a
new clinical study that evaluates the effectiveness of Oncoprex in combination
with a checkpoint inhibitor for the treatment of NSCLC.
NSCLC is the most common type of lung cancer. It accounts
for approximately 85 percent of all lung cancer cases and, despite the
development of innovative treatment strategies, the survival rate for lung
cancer patients has not improved significantly over the past 25 years (http://ibn.fm/zQh71).
Breakthrough technologies and therapeutic approaches like
those developed by Genprex could take cancer treatment solutions to a new level
of effectiveness. Gene therapy could be the one innovative development that
will contribute to curing what’s currently incurable, and companies like
Genprex are spearheading these efforts.
For more information, visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment